|
Trevor Twose is a Founder and CEO of Mithridion. Dr Twose has more than 30 years of international experience, covering general management, R&D, business and corporate development, and finance in start-up, development-stage and established pharmaceutical, diagnostics and biotechnology companies. Most recently he served as the founding CEO and Research Director of Scarab Genomics LLC, a spin-out from the University of Wisconsin, Madison. Previously, he was Chief Executive of Medical Solutions plc, a $25m turnover London Stock Exchange-listed medical products group. Prior to that, he was a founder and first CEO of a cancer therapy company EPTTCO (now Proacta Therapeutics, Inc, San Diego, CA), which brought together science and technology from leading UK and New Zealand cancer researchers. For six years he was with Xenova Group plc, a listed UK/US biopharmaceutical company, latterly as a main board director and CFO. During his tenure, he played pivotal roles in raising over $90 million in US and European capital markets, and in the company’s IPOs on Nasdaq (symbol: XNVA) in the USA and on the London Stock Exchange. Earlier, he was as an independent consultant, with a wide range of US and European clients. He was a founder of a new diagnostics division of ICI (now AstraZeneca) and played a pivotal role in launching its service business Cellmark Diagnostics - now part of Orchid Cellmark (Nasdaq: ORCH) - in the USA and Europe. The business is the world leader in human identity testing, with more than $60m per year in revenues. Dr Twose spent 11 years at ICI (now AstraZeneca) Pharmaceuticals, where he led multidisciplinary teams of arthritis, inflammation and immunology researchers, genetic engineers and medicinal chemists based at labs in the UK and France. He served as a member of the UK government Pharmaceuticals, Biotechnology & Devices Technology Foresight panel, and as a council member and director of the UK national BioIndustry Association. | 